Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma

Cancer

Volumn 115, Issue 9, 2009, Pages 1867-1874

  Ramondetta, Lois M ^a,b   Johnson, Alaina J ^b   Sun, Charlotte C ^b   Atkinson, Neely ^b   Smith, Judith A ^b,c   Jung, Maria S ^b   Broaddus, Russel ^b   Iyer, Revathy B ^b   Burke, Thomas ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Endometrial cancer; Endometrial stromal sarcoma; Hormone therapy; Mifepristone; RU 486

Indexed keywords

CARBOPLATIN; CIMETIDINE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MIFEPRISTONE; PACLITAXEL; PLATINUM; PROGESTERONE RECEPTOR;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BIOPSY; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; CORTICOTROPIN BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIOID CARCINOMA; ENDOMETRIUM SARCOMA; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RATING SCALE; RECURRENT CANCER; SIDE EFFECT;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, ENDOMETRIOID; FEMALE; HORMONE ANTAGONISTS; HUMANS; MIDDLE AGED; MIFEPRISTONE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, PROGESTERONE; RECURRENCE; SARCOMA, ENDOMETRIAL STROMAL;

EID: 65749117600     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24197     Document Type: Article

References (42)

1. Jemal A. Siegel R. Ward E. et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. (Pubitemid 46148091)
2. Kleine W. Maier T. Geyer H. et al. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol. 1990;38:59-65. (Pubitemid 20206227)
3. Podratz K. C. O'Brien P. C. Malkasian C. D. Jr. et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol. 1985;66:106-110. (Pubitemid 15047395)
4. Gadducci A. Sartori E. Landoni F. et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;63:247-253. (Pubitemid 26398607)
5. Balleine R. L. Earls P. J. Webster L. R. et al. Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. Int J Gynecol Pathol. 2004;23:138-144. (Pubitemid 38391773)
6. Chu M. C. Mor G. Lim C. et al. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003; 90:170-176. (Pubitemid 37338093)
7. Pink D. Lindner T. Mrozek A. et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol. 2006; 101:464-469. (Pubitemid 44251067)
8. Pustilnik T. Burke TW. Adjuvant chemotherapy for highrisk endometrial cancer. Semin Radiat Oncol. 2000; 10: 23-28. (Pubitemid 30044145)
9. Decruze S. B. Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17:964-978. (Pubitemid 47414814)
10. Piver M. S. Barlow J. J. Lurain J. R. et al. Medroxyprogesterone acetate (Depo-Provera) versus hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer. 1980;45:268-272. (Pubitemid 10212189)
11. Thigpen T. Blessing J. Hatch et al. A randomized trial of medroxyprogesterone acetate (MPA) 200 mg versus 1000 mg daily in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study [abstract]. Proc Am Soc Clin Oncol. 1991;10:185.
12. Bohr L. Thomsen CF. Low-grade stromal sarcoma: a benign appearing malignant uterine tumour; a review of current literature. Differential diagnostic problems illustrated by 4 cases. Eur J Obstet Gynecol Reprod Biol. 1991;39; 63-69.
13. Thigpen J. T. Brady M. F. Alvarez R. D. et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999; 17: 1736-1744. (Pubitemid 29269242)
14. Eisinger S. H. Bonfiglio T. Fiscella K. Meldrum S. Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005; 12:227-233. (Pubitemid 40800387)
15. Navo M. A. Smith J. A. Gaikwad A. Burke T. Brown J. Ramondetta LM. In vitro evaluation of die growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol. 2008;62:483-489. (Pubitemid 350191842)
16. Schneider C. C. Gibb R. K. Taylor D. D. et al. Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig. 1998;5:334-338. (Pubitemid 28525422)
17. Zeng C. Gu M. Huang H. [A clinical control study on die treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone.] Zhonghua Fu Chan Ke Za Zhi. 1998;33:490-492.
18. Hyder S. M. Murthy L. Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 1998;58:392-395. (Pubitemid 28087395)
19. Sun M. Zhu G. Zhou L. [Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata.] Zhonghua Fu Chan Ke Za Zhi. 1998;33:227-231.
20. Sitruk-Ware R. Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003;68:409-420. (Pubitemid 38112739)
21. Spitz I. M. Bardin CW. Mifepristone (RU 486) -a modulator of progestin and glucocorticoid action. N Engl J Med. 1993;329:404-412. (Pubitemid 23219347)
22. Danco Laboratories. Product Labeling for Health Care Professionals. New York, NY: Danco Laboratories, LLC; 2005.
23. Leonhardt S. A. Edwards DP. Mechanism of action of progesterone antagonists. Exp Biol Med (Maywood). 2002;227: 969-980. (Pubitemid 36008304)
24. Speroff L. Glass R. H. Kase N. G. eds. Clinical Gynecologic Endocrinology and Infertility, 5th ed. Baltimore: Williams and Wilkins; 1994.
25. Chabbert-Buffet N. Meduri G. Bouchard P. Spirz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update. 2005;11:293-307. (Pubitemid 40674206)
26. Liu Z. Auboeuf D. Wong J. et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci USA. 2002; 99:7940-7944. (Pubitemid 34650984)
27. Nayak N. R. Ghosh D. Sengupta J. Effects of luteal phase administration of mifepristone (RU486) and prostaglandin analogue or inhibitor on endometrium in the rhesus monkey. Hum Reprod. 1998;13:1047-1056. (Pubitemid 28239219)
28. Saegusa M. Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer. 1998;83:111-121. (Pubitemid 28299636)
29. Bygdeman M. Danielsson K. G. Marions L. et al. Contraceptive use of antiprogesrin. Eur J Contracept Reprod Health Care. 1999;4:103-107.
30. Liu G. Franssen E. Fitch M. I. et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115. (Pubitemid 27021524)
31. Klijn J. G. de Jong F. H. Bakker G. H. et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 1989;49:2851-2856. (Pubitemid 19148614)
32. Rocereto T. F. Saul H. M. Aikins JA, Jr. et al. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol. 2000;77:429-432. (Pubitemid 30368562)
33. Romieu G. Maudelonde T. Ulmann A. et al. The antiprogesrin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer. 1987;74:455-461. (Pubitemid 17135278)
34. Cella D. F. Tulsky D. S. Gray G. et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579. (Pubitemid 23071057)
35. Portenoy R. K. Thaler H. T. Kornblith A. B. et al. The Memorial Symptom Assessment Scale; an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A:1326-1336. (Pubitemid 24322071)
36. Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
37. Li A. Felix J. C. Minoo P. et al. Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril. 2005;84:202-211. (Pubitemid 40991482)
38. Fiorica J. V. Brunette V. L. Hanjani P. et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10-14. (Pubitemid 38147365)
39. El Etreby M. F. Liang Y. Lewis RW. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate. 2000;43:31-42. (Pubitemid 30164241)
40. Rose F. V. Barnea ER. Response of human ovarian carcinoma cell lines to antiprogesrin mifepristone. Oncogene. 1996;12:999-1003. (Pubitemid 26104441)
41. Hyder S. M. Chiappetta C. Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer. 2001;92:469-473. (Pubitemid 32319417)
42. Kamradt M. C. Mohideen N. Vaughan AT. RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells. Gynecol Oncol. 2000;77:177-182. (Pubitemid 30217322)